)
Visual
test
Solid Biosciences
Solid Biosciences (SLDB) investor relations material
Solid Biosciences Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary19 Mar, 2026
Company overview and business model
Focuses on developing gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy and Friedreich's ataxia.
Pipeline includes SGT-003, SGT-212, SGT-501, SGT-601, and additional assets at various development stages.
Mission centers on improving daily lives of patients with severe genetic diseases.
Financial performance and metrics
Raised approximately $240 million in gross proceeds from a private placement in March 2026, before fees and expenses.
42,780,739 shares registered for resale, including 27,807,482 shares issuable upon exercise of pre-funded warrants.
Use of proceeds and capital allocation
Will not receive any proceeds from the resale of shares by selling stockholders.
Proceeds from the private placement were received by the company; resale proceeds go to selling stockholders.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Solid Biosciences
- Strong clinical progress and $240M financing extend cash runway into 2028 despite higher net loss.SLDB
Q4 202520 Mar 2026 - Registering 1.3M shares for resale after asset acquisition; no proceeds to the company.SLDBRegistration filing19 Mar 2026
- Gene therapy trials for DMD and FA advance with FDA alignment and innovative delivery methods.SLDBGuggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026
- SGT-003 interim data showed strong efficacy; Q3 net loss $45.8M, cash runway into H1 2027.SLDBQ3 202510 Feb 2026
- Net loss widened to $39.5M in Q2 2025 as R&D surged; cash runway extends into 2027.SLDBQ2 202510 Feb 2026
- Q1 2025 net loss rose to $39.3M as R&D spending increased, with cash runway into 1H 2027.SLDBQ1 202510 Feb 2026
- Strong pipeline progress and extended cash runway position for key clinical milestones in 2025.SLDBQ4 202410 Feb 2026
- SGT-003 gene therapy shows early safety, with broad clinical expansion and strong financial runway.SLDBH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- Advancing next-gen gene therapies with global trials, strong demand, and data expected by early 2025.SLDBChardan's 8th Annual Genetic Medicines Conference20 Jan 2026
Next Solid Biosciences earnings date
Q1 202612 May, 2026
Solid Biosciences
Next Solid Biosciences earnings date
Q1 202612 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage